Astellas Pharma (YPH) Ratios
Astellas Pharma Ratios
DE:YPH's free cash flow for Q2 2026 was $216.06B. For the 2026 fiscal year, DE:YPH's free cash flow was decreased by $-13.44B and operating cash flow was $229.49B. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 26 | Mar 25 | Mar 24 | Mar 23 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.13 | 1.17 | 0.93 | 1.45 | 1.34 |
| Quick Ratio | 0.85 | 0.90 | 0.74 | 1.21 | 1.12 |
| Cash Ratio | 0.18 | 0.23 | 0.26 | 0.52 | 0.46 |
| Solvency Ratio | 0.14 | 0.28 | 0.09 | 0.22 | 0.23 |
| Operating Cash Flow Ratio | 0.19 | 0.46 | 0.13 | 0.45 | 0.37 |
| Short-Term Operating Cash Flow Coverage | 0.71 | 2.30 | 0.37 | 4.37 | 1.63 |
| Net Current Asset Value | $ -624.94B | $ -314.24B | $ -778.88B | $ 101.39B | $ 51.27B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.28 | 0.16 | 0.28 | 0.08 | 0.09 |
| Debt-to-Equity Ratio | 0.62 | 0.31 | 0.63 | 0.13 | 0.15 |
| Debt-to-Capital Ratio | 0.38 | 0.24 | 0.39 | 0.12 | 0.13 |
| Long-Term Debt-to-Capital Ratio | 0.27 | 0.15 | 0.22 | 0.03 | 0.00 |
| Financial Leverage Ratio | 2.21 | 1.95 | 2.24 | 1.63 | 1.60 |
| Debt Service Coverage Ratio | 1.60 | 1.92 | 0.39 | 2.47 | 1.28 |
| Interest Coverage Ratio | 14.46 | 29.83 | 19.01 | 32.51 | 44.46 |
| Debt to Market Cap | 0.33 | 0.13 | 0.31 | 0.04 | 0.04 |
| Interest Debt Per Share | 533.33 | 323.84 | 566.05 | 114.72 | 117.69 |
| Net Debt to EBITDA | 1.62 | 0.49 | 3.43 | -0.74 | -0.43 |
| Profitability Margins | |||||
| Gross Profit Margin | 81.74% | 74.55% | 81.76% | 81.01% | 80.48% |
| EBIT Margin | 13.78% | 18.26% | 2.31% | 8.87% | 12.49% |
| EBITDA Margin | 24.19% | 27.36% | 12.18% | 15.83% | 18.60% |
| Operating Profit Margin | 13.37% | 19.62% | 11.10% | 18.80% | 16.97% |
| Pretax Profit Margin | 1.63% | 17.60% | 1.56% | 8.72% | 12.10% |
| Net Profit Margin | 2.65% | 13.63% | 1.06% | 6.50% | 9.57% |
| Continuous Operations Profit Margin | 2.65% | 13.63% | 1.06% | 6.50% | 9.54% |
| Net Income Per EBT | 162.46% | 77.42% | 68.26% | 74.58% | 79.09% |
| EBT Per EBIT | 12.22% | 89.73% | 14.02% | 46.37% | 71.31% |
| Return on Assets (ROA) | 1.52% | 8.17% | 0.48% | 4.02% | 5.32% |
| Return on Equity (ROE) | 3.35% | 15.92% | 1.07% | 6.55% | 8.50% |
| Return on Capital Employed (ROCE) | 11.22% | 17.87% | 7.80% | 16.49% | 13.38% |
| Return on Invested Capital (ROIC) | 9.98% | 12.52% | 4.39% | 11.70% | 9.56% |
| Return on Tangible Assets | 2.82% | 13.69% | 1.00% | 6.31% | 8.83% |
| Earnings Yield | 1.96% | 6.46% | 0.58% | 2.88% | 3.51% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.96 | 2.81 | 3.00 | 3.55 | 3.39 |
| Payables Turnover | 4.01 | 2.73 | 1.58 | 2.06 | 1.94 |
| Inventory Turnover | 1.17 | 1.64 | 1.18 | 1.65 | 1.65 |
| Fixed Asset Turnover | 5.81 | 5.97 | 5.46 | 5.30 | 4.82 |
| Asset Turnover | 0.57 | 0.60 | 0.45 | 0.62 | 0.56 |
| Working Capital Turnover Ratio | 78.46 | 12.46 | 13.77 | 5.42 | 5.02 |
| Cash Conversion Cycle | 343.07 | 217.98 | 201.06 | 146.09 | 139.92 |
| Days of Sales Outstanding | 123.34 | 129.97 | 121.76 | 102.86 | 107.70 |
| Days of Inventory Outstanding | 310.71 | 221.93 | 310.41 | 220.74 | 220.83 |
| Days of Payables Outstanding | 90.97 | 133.92 | 231.11 | 177.51 | 188.61 |
| Operating Cycle | 434.05 | 351.90 | 432.17 | 323.60 | 328.53 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 112.62 | 316.15 | 96.18 | 180.09 | 139.18 |
| Free Cash Flow Per Share | 91.95 | 283.92 | 50.18 | 131.44 | 97.85 |
| Dividend Paid and CapEx Coverage Ratio | 1.21 | 2.92 | 0.87 | 1.74 | 1.59 |
| Capital Expenditure Coverage Ratio | 5.45 | 9.81 | 2.09 | 3.70 | 3.37 |
| Operating Cash Flow Coverage Ratio | 0.22 | 1.00 | 0.17 | 1.64 | 1.21 |
| Operating Cash Flow to Sales Ratio | 0.11 | 0.26 | 0.11 | 0.22 | 0.20 |
| Free Cash Flow Yield | 6.36% | 11.27% | 3.06% | 6.98% | 5.12% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 51.02 | 15.48 | 172.65 | 34.72 | 28.49 |
| Price-to-Sales (P/S) Ratio | 1.35 | 2.11 | 1.84 | 2.26 | 2.73 |
| Price-to-Book (P/B) Ratio | 1.71 | 2.46 | 1.84 | 2.27 | 2.42 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 15.73 | 8.87 | 32.71 | 14.33 | 19.53 |
| Price-to-Operating Cash Flow Ratio | 12.84 | 7.97 | 17.06 | 10.46 | 13.73 |
| Price-to-Earnings Growth (PEG) Ratio | 0.26 | 0.03 | -2.09 | -1.81 | 8.60 |
| Enterprise Value Multiple | 7.22 | 8.19 | 18.49 | 13.52 | 14.24 |
| Enterprise Value | 3.34T | 4.80T | 3.61T | 3.25T | 3.43T |
| EV to EBITDA | 7.22 | 8.19 | 18.49 | 13.52 | 14.24 |
| EV to Sales | 1.75 | 2.24 | 2.25 | 2.14 | 2.65 |
| EV to Free Cash Flow | 20.28 | 9.43 | 40.15 | 13.59 | 18.96 |
| EV to Operating Cash Flow | 16.56 | 8.47 | 20.95 | 9.92 | 13.33 |
| Tangible Book Value Per Share | -14.34 | 219.29 | -154.20 | 339.03 | 288.61 |
| Shareholders’ Equity Per Share | 845.30 | 1022.21 | 889.98 | 828.54 | 789.48 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.62 | 0.23 | 0.32 | 0.25 | 0.21 |
| Revenue Per Share | 1068.21 | 1194.37 | 894.27 | 834.40 | 700.74 |
| Net Income Per Share | 28.35 | 162.77 | 9.50 | 54.24 | 67.08 |
| Tax Burden | 1.62 | 0.77 | 0.68 | 0.75 | 0.79 |
| Interest Burden | 0.12 | 0.96 | 0.68 | 0.98 | 0.97 |
| Research & Development to Revenue | 0.17 | 0.15 | 0.18 | 0.18 | 0.19 |
| SG&A to Revenue | 0.44 | 0.40 | 0.46 | 0.42 | 0.42 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 3.97 | 1.94 | 10.12 | 2.48 | 1.64 |
Currency in JPY